American Diabetes Association
6 files

Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2DM and NGT Subjects

posted on 2024-03-21, 16:56 authored by Xi Chen, Devjit Tripathy, Robert Chilton, Andrea Hansis-Diarte, Marzieh Salehi, Carolina Solis-Herrera, Eugenio Cersosimo, Ralph A DeFronzo

Acute and chronic SGLT-2 inhibition increase endogenous glucose production (EGP). However, the organ - liver versus kidney - responsible for the increase in EGP has not been identified. 20 T2DM and 12 NGT subjects received [3-3H]-glucose infusion (to measure total EGP) in combination with arterial and renal vein catheterization and PAH infusion for determination of renal blood flow. Total EGP, net renal arteriovenous balance, and renal glucose production were measured before and 4 hours after dapagliflozin and placebo administration. Following DAPA, EGP increased in both T2D and NGT from baseline to 240 minutes, while there was a significant time-related decrease after placebo in T2D. Renal glucose production at baseline was <5% of basal EGP in both groups and did not change significantly following DAPA in either NGT and T2D. Renal glucose uptake (sum of tissue glucose uptake plus glucosuria) increased in both T2D and NGT following DAPA (P<0.05 vs placebo). The increase in RGU was entirely explained by the increase in glucosuria. Single dose of dapagliflozin significantly increased EGP, which primarily is explained by an increase in hepatic glucose production, establishing the existence of a novel renal-hepatic axis.


This work was supported by National Institutes of Health grant DK-24092-36 (to R.A.D.) and support from Astra Zeneca. D.T.’s salary is supported by the South Texas Veterans Health Care System, Audie L. Murphy VA Hospital.


Usage metrics



    Ref. manager